Quick Answer
Wave Life Sciences Ltd. reported Cash and Equivalents of $602.07 million for fiscal year 2025.
Wave Life Sciences Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $602.07M | +99.3% |
| 2024 | $302.08M | +50.8% |
| 2023 | $200.35M | +126.4% |
| 2022 | $88.50M | -41.2% |
| 2021 | $150.56M | -18.4% |
| 2020 | $184.50M | +25.4% |
| 2019 | $147.16M | -15.8% |
| 2018 | $174.82M | +22.7% |
| 2017 | $142.50M | -5.2% |
| 2016 | $150.29M | -6.8% |
| 2015 | $161.22M | +15283.6% |
| 2014 | $1.05M | +138.7% |
| 2013 | $439.0K | +15.8% |
| 2012 | $379.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $196.22M | -36.9% | -5.9% |
| June 30, 2025 | $208.48M | +35.4% | -14.2% |
| March 31, 2025 | $243.07M | +34.4% | -19.5% |
| December 31, 2024 | $302.08M | +50.8% | -2.9% |
| September 30, 2024 | $310.95M | +122.2% | +102.0% |
| June 30, 2024 | $153.96M | -11.0% | -14.9% |
| March 31, 2024 | $180.92M | -12.8% | -9.7% |
| December 31, 2023 | $200.35M | +126.4% | +43.2% |
- Wave Life Sciences Ltd. showed an increase of +99.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Wave Life Sciences Ltd.’s cash and equivalents has grown by 158757.0% (from $379.0 thousand to $602.07 million).
- The most recent figure is from Wave Life Sciences Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: